Biodesix Inc.

19.29+0.1500+0.78%Vol 7551Y Perf 50.59%
Apr 16th, 2021 09:30 DELAYED
BID18.51 ASK19.24
Open19.29 Previous Close19.14
Pre-Market- After-Market-
 - -%  - -
Target Price
26.00 
Analyst Rating
— — 0.00
Potential %
34.78 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★ —    48.42
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+ —    51.20
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap512.69M 
Earnings Rating
Price Range Ratio 52W %
39.92 
Earnings Date
16th Mar 2021

Today's Price Range

19.2919.29

52W Range

10.8531.99

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.00%
1 Month
-11.92%
3 Months
-31.64%
6 Months
-
1 Year
50.59%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BDSX19.290.15000.78
AAPL134.34-0.1600-0.12
GOOG2 292.91-3.7500-0.16
MSFT259.680.18000.07
XOM56.60-0.3800-0.67
WFC42.970.73001.73
JNJ160.780.39000.24
FB306.90-0.9200-0.30
GE13.47-0.0800-0.59
JPM153.501.33000.87
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.48-0.2547.92
Q03 2020--31.93-
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.48
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume755
Shares Outstanding26.58M
Trades Count10
Dollar Volume2.55M
Avg. Volume101.36K
Avg. Weekly Volume21.47K
Avg. Monthly Volume59.50K
Avg. Quarterly Volume99.56K

Biodesix Inc. (NYSE: BDSX) stock closed at 19.14 per share at the end of the most recent trading day (a 0.95% change compared to the prior day closing price) with a volume of 19.57K shares and market capitalization of 512.69M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 186 people. Biodesix Inc. CEO is Scott Hutton.

The one-year performance of Biodesix Inc. stock is 50.59%, while year-to-date (YTD) performance is -5.06%. BDSX stock has a five-year performance of %. Its 52-week range is between 10.85 and 31.99, which gives BDSX stock a 52-week price range ratio of 39.92%

Biodesix Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 12.29, a price-to-sale (PS) ratio of 11.06, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.75%, a ROC of -% and a ROE of 34.08%. The company’s profit margin is -68.81%, its EBITDA margin is -84.20%, and its revenue ttm is $45.56 Million , which makes it $1.71 revenue per share.

Of the last four earnings reports from Biodesix Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Biodesix Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Biodesix Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Biodesix Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biodesix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biodesix Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.00, ATR14 : 2.06, CCI20 : -24.63, Chaikin Money Flow : -0.06, MACD : -1.16, Money Flow Index : 44.92, ROC : 13.46, RSI : 41.58, STOCH (14,3) : 59.47, STOCH RSI : 1.00, UO : 43.50, Williams %R : -40.53), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biodesix Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Biodesix Inc.

Biodesix Inc is a data-driven diagnostic solutions company. The company's artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The revenue is derived from two sources namely, providing diagnostic tests and providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services.

CEO: Scott Hutton

Telephone: +1 303 417-0500

Address: 2970 Wilderness Place, Boulder 80301, CO, US

Number of employees: 186

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

75%25%

Bearish Bullish

75%25%

Bearish Bullish

70%30%

News

Stocktwits